Original release date: April 6, 2023
Access to this course expires on: March 16, 2026 at 11:59 PM Pacific Time
This is an exciting time in pathology as pathology is transforming, entering into an era of rapid discoveries and technological advances based on robust advances. Next generation pathology tools, including new technological advances in anatomical pathology, are already being deployed, and many more are rapidly getting developed in research settings. The ongoing technological advances in digital whole slide imaging scanners, image visualization methods, and the integration of artificial intelligence (AI)-derived algorithms into pathology applications are already being used by some pathologists. The benefits of these tools include ease of remote access to cases via the cloud, avoidance of physical storage space, and no risk of deterioration of staining quality or breakage of slides, to name a few. There are advances in genomics, spatiomics, biomarker assessment, multiplexing, and other advanced imaging tools that can now provide single-cell and 3D information to anatomical pathologists. The focus of this course is to provide practical insights into the status of several technological advances in anatomical pathology, such as whole slide imaging, artificial intelligence, augmented reality, genomics, bioinformatics, multiplexing, and advanced imaging tools such as 3D rendering of pathology images. The speakers will provide insights into how close we are today to reaping the benefits of these tools and solutions for routine pathology practice. This course material will allow pathologists to be better prepared to adopt and implement these advances in their daily practice. Expert speakers in these areas will provide an overview of the complexities and barriers of implementing these tools for widespread adoption. Some of the barriers that will be highlighted include cost, technical glitches, interoperability, and, most importantly, professional hesitation to adopt new technology.
Practicing academic and community pathologists, and pathologists-in-training
Upon completion of this educational activity, learners will be able to:
Continuing Medical Education
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 5.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any financial relationship(s) that have occurred within the last 24 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and mitigated all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships: David L. Rimm, MD, PhD: Consultant, Cepheid; Danaher; Grant or Research Support, Cepheid; Richard M. Levenson, MD, Stock Ownership, Histolix, Inc.;
The following faculty reported no relevant financial relationships: Anil Parwani, MD, PhD, MBA, Liron Pantanowitz, MD, PhD, MHA, Toby C. Cornish, MD, PhD, Faisal Mahmood, PhD, Laura Barisoni, MD, Alexis Byrne Carter, MD, George Jabboure Netto, MD
The following Education Committee members reported financial relationships: Jennifer Gordetsky: Consultant: Janssen; Tamara Lotan: Grant or Research Support: Myriad; Liron Pantanowitz: Consultant: Hamamatsu, Praxis Medical; Advisory Board Member: Ibex; David Schaeffer: Consultant: Alimentiv, Astaellas, AstraZeneca, NEED Inc;
Stock Ownership: Satisfai Health Inc.; Lynette Sholl: Grant or Research Support: Bristol Myers Squibb; Consultant: GV20 Therapeutics, Genentech, Lilly; Advisory Board Member: AstraZeneca; Charles “Matt” Quick: Consultant: Myriad Genetics
The following Education Committee members reported no relevant financial relationships: Adebowale Adeniran, Kimberly Allison, Justin Bishop, Laura Collins, Carla Ellis, Yuri Fedoriw, Karen Fritchie, Sarah Gibson, Kristin Jensen, Levon Katsakhyan, Melinda Lerwill, M. Beatriz Lopes, Terri Mason, Julia Naso, Nicole Panarelli, Carlos Parra-Herran, Rajiv Patel, Olga Weinberg, Ilan Weinreb, Maria Westerhoff, Rhonda Yantiss
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.